Sugi Predict

Sugi Predict / Compounds / SCHEMBL268592

SCHEMBL268592

SCHEMBL268592

COc1ccc2c(c1)CCC2=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.56
▸ HTT P42858 1/20 0.56
▸ MIF P14174 3/20 0.55
▸ METAP1 P53582 1/20 0.54
▸ CASP1 P29466 1/20 0.53
▸ CASP7 P55210 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ MAOB P27338 1/20 0.53
▸ CYP26A1 O43174 2/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ LMNA P02545 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ CYP19A1 P11511 1/20 0.52
▸ MPO P05164 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ HRH3 Q9Y5N1 2/20 0.51
▸ GLA P06280 1/20 0.51
▸ PRNP P04156 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL28454486 0.98 KDM4E (0.54) KDM4EHTTMIFMETAP1CASP1
SCHEMBL6130607 0.93 MAPK14 (0.56) KDM4EHTTMIFMETAP1MAOB
SCHEMBL115638 0.89 MAOA (0.58) KDM4EHTTMETAP1MAOBCYP19A1
SCHEMBL29756894 0.89 MAOA (0.58) KDM4EHTTMETAP1MAOBPRNP
SCHEMBL1495967 0.89 MAOA (0.58) KDM4EHTTMETAP1MAOBPRNP
SCHEMBL3860885 0.86 MAPK14 (0.50) METAP1MAOBCYP19A1
SCHEMBL1745460 0.86 HSD17B1 (0.63) KDM4EHTTCASP1CASP7HSD17B10
SCHEMBL17108416 0.86 MPO (0.59) KDM4EHTTMIFMETAP1CYP26A1
SCHEMBL29392039 0.85 MAOB (0.54) KDM4EHTTMETAP1MAOBALDH1A1
SCHEMBL251842 0.85 MAOB (0.54) KDM4EHTTMETAP1MAOBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 831 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113861113-B Preparation and application of fused ring pyridine compound and derivative thereof 中国科学院福建物质结构研究所 2022-12-06 — — CN claimed
CN-111303930-B Method for hydrosilylation reaction of carbonyl compound in biological oil 河北工业大学 2022-02-08 — — CN claimed
CN-113861113-A Preparation and application of fused ring pyridine compound and derivative thereof 中国科学院福建物质结构研究所 2021-12-31 — — CN claimed
CN-112574078-A 2-sulfuryl-2, 3-dihydro-1-indanone and derivatives and synthesis method thereof 湖南工程学院 2021-03-30 — — CN claimed
CN-111303930-A Method for hydrosilylation reaction of carbonyl compound in biological oil 河北工业大学 2020-06-19 — — CN claimed
US-10092786-B2 Fire extinguishing composition comprising aldoketones compound XI'AN WESTPEACE FIRE TECHNOLOGY CO., LTD. (CN) 2018-10-09 — — US claimed
US-20160332016-A1 Fire Extinguishing Composition Comprising Aldoketones Compound NANO FIRE, LLC 2016-11-17 — — US claimed
US-5663029-A DEVELOPMENT OF LATENT IMAGE, TRANSFERRING TO FORM RECORDING SHEETS, COATING A SUBSTRATE USING POLYMERS XEROX CORPORATION (US) 1997-09-02 — — US claimed
EP-0275104-B1 Process for preparing 2,3-dihydro-1H-imidazolylalkoxyindene derivatives and pharmaceutically acceptable salts, and intermediate therefor FERRER INT (ES) 1994-01-19 — — EP claimed
US-4843165-A Process for preparing a 2,3-dihydro-1H-imidazolyl-ethoxy indene antithrombotic agent and its pharmaceutically acceptable salts FERRER INTERNACIONAL S.A. (ES) 1989-06-27 — — US claimed
EP-0275104-A2 Process for preparing 2,3-dihydro-1H-imidazolylalkoxyindene derivatives and pharmaceutically acceptable salts, and intermediate therefor FERRER INTERNACIONAL, S.A. (ES) 1988-07-20 — — EP claimed
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 — — EP disclosed
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 — — EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 — — US disclosed
US-4147795-A ENZYME INHIBITORS PFIZER INC. (US) 1979-04-03 — — US disclosed
US-4117230-A ANTIDIABETIC AGENTS PFIZER INC. (US) 1978-09-26 — — US disclosed
US-4075223-A NONSTEROIDAL ELI LILLY AND COMPANY (US) 1978-02-21 — — US disclosed
US-4017546-A AROYL PHENYL INDENES AND AROYL PHENYL NAPHTHALENES ELI LILLY AND COMPANY (US) 1977-04-12 — — US disclosed
US-3984552-A 6-Oxo-7-substituted and 7,7-disubstituted-6H-indeno-[5,4-b]furan (and thiophene) carboxylic acids MERCK & CO., INC. (US) 1976-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BCL2A1, BAX KDM4E 4602/4885HTT 4207/4885MIF 2773/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KDM4E 773/4885HTT 1323/4885MIF 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.